Ablynx Announces Topline Results from the Phase II Study of Vobarilizumab in Patients with Systemic Lupus Erythematosus
March 26, 2018
Source: Ablynx Press Release 3.26.18
Ablynx today announced that the Phase II dose-ranging study of vobarilizumab, the Company's anti-IL-6R...